Adoptive T-Cell Therapy for Cancer

James C. Yang, Steven A. Rosenberg

Research output: Chapter in Book/Report/Conference proceedingConference contribution

101 Scopus citations


Recent developments have demonstrated that immunotherapies are capable of achieving durable antitumor responses in patients with metastatic cancer. One modality that has been able to induce durable complete regressions in patients with melanoma has been adoptive cell therapy (ACT). This has slowly been expanded to other cancer types using new approaches such as genetically engineered T-cells and other methods of antigen targeting. It now appears that immune targeting of mutated "neoantigens" plays a major role in successful ACT, as well as in other immunotherapies such as checkpoint inhibitors. This realization presents not only new challenges to ACT but also new opportunities in that all tumors now may have potential antigens to attack that can be revealed by tumor genomic sequencing. There are a variety of exciting approaches to translate these new findings into clinical trials applying ACT to the majority of cancer types.

Original languageEnglish (US)
Title of host publicationTumor Immunology, 2016
EditorsRobert D. Schreiber
PublisherAcademic Press Inc.
Number of pages16
ISBN (Print)9780128051566
StatePublished - 2016

Publication series

NameAdvances in Immunology
ISSN (Print)0065-2776
ISSN (Electronic)1557-8445


  • Adoptive cell therapy
  • Immunotherapy
  • Neoantigens
  • T-cell transfer
  • Tumor antigens
  • Tumor infiltrating lymphocytes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Adoptive T-Cell Therapy for Cancer'. Together they form a unique fingerprint.

Cite this